Sanuwave Health (SNWV)
NASDAQ:SNWV
Want to see SNWV full AI Analyst Report?
SNWV Stock Chart & Stats
$31.30
$1.30(5.42%)
At close: 4:00 PM EST
$31.30
$1.30(5.42%)
Day’s Range― - ―
52-Week Range$16.27 - $46.59
Previous CloseN/A
Volume17.14K
Average Volume (3M)78.76K
Market Cap
$157.02M
Enterprise Value$188.14M
Total Cash (Recent Filing)$11.96M
Total Debt (Recent Filing)$22.97M
Price to Earnings (P/E)21.6
Beta0.78
Next Earnings
May 08, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.87
Shares Outstanding8,594,209
10 Day Avg. Volume75,518
30 Day Avg. Volume78,757
Financial Highlights & Ratios
PEG Ratio-0.18
Price to Book (P/B)157.84
Price to Sales (P/S)5.80
P/FCF Ratio132.13
Enterprise Value/Market Cap1.20
Enterprise Value/Revenue4.27
Enterprise Value/Gross Profit5.69
Enterprise Value/Ebitda30.21
Forecast
1Y Price Target
$51.00Price Target Upside62.94% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)0.4
Revenue Forecast (FY)$52.07M
Bulls Say, Bears Say
Bulls Say
Revenue & System Sales MomentumSustained unit growth and multi-year revenue rebound reflect durable product adoption and market penetration. A larger installed base supports recurring consumables and service revenue, improving revenue predictability and creating a foundation for scalable margin and cash generation over the medium term.
High Gross Margins & Consumables DemandPersistent ~77% gross margin and rising consumables volumes indicate strong unit economics and recurring revenue leverage. High margin consumables create durable revenue streams that can sustain profitability through sales cycles and support reinvestment in sales, R&D, and channel expansion over the coming quarters.
Reduced Debt And Improved LiquidityMarked debt reduction materially lowers interest burden and refinancing risk, improving financial flexibility. Combined with stronger current assets and cash, the balance-sheet repair increases the firm's ability to fund growth initiatives, manage audits/settlements, and sustain operations through industry volatility.
Bears Say
Thin Equity & High LeverageExtremely low equity relative to debt leaves a limited capital cushion if operational performance weakens. High leverage magnifies downside risk from revenue shocks or working-capital swings, constrains strategic flexibility, and could force dilutive financing or restrictive covenants over the medium term.
Uneven Cash ConversionLow cash conversion versus reported earnings and negative free cash flow growth point to earnings that are not fully translating into cash. This raises sustainability concerns for funding working capital, capex, and debt service without external financing, especially during revenue volatility.
CMS Reimbursement Shock & Customer ChurnA structural reduction in CMS reimbursement and heightened audits have depressed practitioner economics and caused meaningful customer attrition. Regulatory-driven demand contraction and heightened audit risk can depress volumes, slow adoption, and lengthen the path to consistent revenue growth.
Sanuwave Health News
SNWV FAQ
What was Sanuwave Health’s price range in the past 12 months?
Sanuwave Health lowest stock price was $16.27 and its highest was $46.59 in the past 12 months.
What is Sanuwave Health’s market cap?
Sanuwave Health’s market cap is $157.02M.
When is Sanuwave Health’s upcoming earnings report date?
Sanuwave Health’s upcoming earnings report date is May 08, 2026 which is in 18 days.
How were Sanuwave Health’s earnings last quarter?
Sanuwave Health released its earnings results on Mar 27, 2026. The company reported $0.87 earnings per share for the quarter, beating the consensus estimate of $0.17 by $0.7.
Is Sanuwave Health overvalued?
According to Wall Street analysts Sanuwave Health’s price is currently Undervalued.
Does Sanuwave Health pay dividends?
Sanuwave Health does not currently pay dividends.
What is Sanuwave Health’s EPS estimate?
Sanuwave Health’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Sanuwave Health have?
Sanuwave Health has 8,594,209 shares outstanding.
What happened to Sanuwave Health’s price movement after its last earnings report?
Sanuwave Health reported an EPS of $0.87 in its last earnings report, beating expectations of $0.17. Following the earnings report the stock price went down -1.273%.
Which hedge fund is a major shareholder of Sanuwave Health?
Currently, no hedge funds are holding shares in SNWV
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Sanuwave Health Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$51.00 (62.94% Upside)
$51.00 (62.94% Upside)
Blogger Sentiment
Bullish
SNWV Sentiment 70%
Sector Average 72%
Sector Average 72%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
32.00%
12-Months-Change
Fundamentals
Return on Equity
-141.56%
Trailing 12-Months
Asset Growth
23.98%
Trailing 12-Months
Company Description
Sanuwave Health
SANUWAVE Health, Inc., a shock wave technology company, researches, develops, and commercializes noninvasive, high-energy, and acoustic shock waves for regenerative medicine and other applications in the United States and internationally. Its shockwaves are used to produce a biological response resulting in the body healing itself through the repair and regeneration of tissue, musculoskeletal, and vascular structures. The company's lead regenerative product is the dermaPACE device for treating diabetic foot ulcers. Its portfolio of healthcare products and product candidates activate biologic signaling and angiogenic responses, including new vascularization and microcirculatory improvement, which helps to restore the body's normal healing processes and regeneration. The company also focuses on applying its Pulsed Acoustic Cellular Expression technology in wound healing, orthopedic, plastic/cosmetic, and cardiac conditions. In addition, it offers UltraMIST, non-contact and non-thermal ultrasound therapy device used to treat diabetic foot ulcers, pressure ulcers, venous leg ulcers, deep tissue pressure injuries, and surgical wounds; and orthoPACE system to treat tendinopathies and acute and nonunion fractures. The company was founded in 2005 and is headquartered in Suwanee, Georgia.
SNWV Company Deck
SNWV Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call presented a mix of strong financial performance and clear operational momentum against meaningful industry headwinds. Highlights include record Q4 revenue ($13.4M, +30% YoY), strong full-year revenue growth (+35%) and an 89% increase in full-year adjusted EBITDA, a record number of UltraMIST system placements (624 units, +67% YoY) and improved liquidity (cash $12M). Offsetting these positives are significant external challenges driven by CMS reimbursement changes and aggressive audits that have pressured some customers (leading to 168 discontinued systems), a sales-tax restatement that added roughly $1.6M of G&A expense in 2025 (and similar prior-year impacts), inventory write-offs related to sunsetting product lines, elevated operating expenses, and near-term guidance that is modest (Q1 up 3%–10% YoY) while the company executes a channel shift to resellers and works through manufacturing qualification timing. Management communicated a clear strategy to capitalize on the market disruption (select reseller partnerships, reseller wholesale placements, focus on active systems and new 'baby elephant' customers) and expects improvement through 2026, but uncertainty remains in the near term.View all SNWV earnings summariesSNWV Stock 12 Month Forecast
Average Price Target
$51.00
▲(62.94% Upside)
Technical Analysis
Cerus
―
Senseonics Holdings
―
Tactile Systems Technology
―
Viemed Healthcare
―
Brainsway
―
Ownership Overview
27.60% Insiders
7.34% Mutual Funds
24.72% Other Institutional Investors
32.37% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---